Evolus (EOLS) Competitors $9.59 -0.37 (-3.71%) Closing price 04:00 PM EasternExtended Trading$9.55 -0.04 (-0.43%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. MLTX, IMVT, HCM, AMRX, OGN, MIRM, APLS, DNLI, VCEL, and NAMSShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Evolus vs. MoonLake Immunotherapeutics Immunovant HUTCHMED Amneal Pharmaceuticals Organon & Co. Mirum Pharmaceuticals Apellis Pharmaceuticals Denali Therapeutics Vericel NewAmsterdam Pharma Evolus (NASDAQ:EOLS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment. Does the MarketBeat Community favor EOLS or MLTX? Evolus received 291 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 82.76% of users gave MoonLake Immunotherapeutics an outperform vote while only 73.19% of users gave Evolus an outperform vote. CompanyUnderperformOutperformEvolusOutperform Votes36373.19% Underperform Votes13326.81% MoonLake ImmunotherapeuticsOutperform Votes7282.76% Underperform Votes1517.24% Which has more volatility & risk, EOLS or MLTX? Evolus has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Which has preferable valuation and earnings, EOLS or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than Evolus. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$275.46M2.33-$61.69M-$0.89-11.19MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$2.30-17.51 Do insiders and institutionals hold more shares of EOLS or MLTX? 90.7% of Evolus shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 5.9% of Evolus shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor EOLS or MLTX? In the previous week, MoonLake Immunotherapeutics had 14 more articles in the media than Evolus. MarketBeat recorded 28 mentions for MoonLake Immunotherapeutics and 14 mentions for Evolus. MoonLake Immunotherapeutics' average media sentiment score of 1.06 beat Evolus' score of 0.82 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 11 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EOLS or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Evolus' net margin of -22.33%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.33% -847.60% -22.15% MoonLake Immunotherapeutics N/A -15.54%-15.09% Do analysts prefer EOLS or MLTX? Evolus currently has a consensus target price of $23.75, indicating a potential upside of 138.45%. MoonLake Immunotherapeutics has a consensus target price of $78.71, indicating a potential upside of 95.42%. Given Evolus' higher possible upside, equities research analysts plainly believe Evolus is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMoonLake Immunotherapeutics beats Evolus on 11 of the 16 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$642.18M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-10.949.1426.7920.05Price / Sales2.33255.59395.67116.44Price / CashN/A65.8538.2534.62Price / Book-27.676.546.864.61Net Income-$61.69M$143.51M$3.22B$248.19M7 Day Performance-0.30%5.60%6.80%2.97%1 Month Performance-4.05%10.06%13.69%16.58%1 Year Performance-24.32%-0.86%18.25%8.16% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.5838 of 5 stars$9.59-3.7%$23.75+147.7%-25.8%$618.33M$275.46M-10.54170Gap UpMLTXMoonLake Immunotherapeutics3.2957 of 5 stars$40.18+4.4%$80.50+100.3%+4.2%$2.57BN/A-31.152Positive NewsAnalyst UpgradeIMVTImmunovant2.7146 of 5 stars$14.55+3.8%$38.33+163.5%-51.4%$2.47BN/A-5.55120Positive NewsHCMHUTCHMED2.2843 of 5 stars$13.92-2.0%$19.00+36.5%-33.9%$2.43B$630.20M0.001,760Positive NewsGap DownAMRXAmneal Pharmaceuticals3.2515 of 5 stars$7.60+2.6%$11.50+51.3%+10.3%$2.36B$2.83B-11.187,600Gap UpOGNOrganon & Co.4.7569 of 5 stars$8.69-0.2%$18.00+107.1%-59.8%$2.26B$6.29B2.6110,000High Trading VolumeMIRMMirum Pharmaceuticals4.094 of 5 stars$45.57+2.9%$59.00+29.5%+79.2%$2.25B$379.25M-22.56140News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.1715 of 5 stars$17.52+1.3%$41.37+136.1%-57.2%$2.20B$781.37M-8.63770Gap UpDNLIDenali Therapeutics4.4205 of 5 stars$14.80+3.0%$33.79+128.3%-29.0%$2.15B$330.53M-5.36430Analyst ForecastVCELVericel2.5621 of 5 stars$42.65+2.2%$60.86+42.7%-14.9%$2.14B$238.54M710.95300Positive NewsNAMSNewAmsterdam Pharma2.5174 of 5 stars$19.22+4.6%$43.00+123.7%-2.5%$2.11B$45.56M-10.224Gap Up Related Companies and Tools Related Companies MoonLake Immunotherapeutics Competitors Immunovant Competitors HUTCHMED Competitors Amneal Pharmaceuticals Competitors Organon & Co. Competitors Mirum Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Denali Therapeutics Competitors Vericel Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
